VALENTIN CABAÑAS PERIANES

Oliver-Caldes A, Espanol-Rego M, Zabaleta A, Gonzalez-Calle V, Navarro-Velazquez S, Inoges S, Lopez-Diaz de Cerio A, Cabanas V, Lopez-Munoz N, Rodriguez-Otero P, Reguera-Ortega JL, Moreno DF, Martinez-Cibrian N, Lopez-Corral L, Perez-Amill L, Martin-Antonio B, Rosinol L, Cid J, Tovar N, Saez-Penataro J, Lopez-Parra M, Olesti E, Guillen E, Varea S, Rodriguez-Lobato LG, Battram AM, Gonzalez-Perez MS, Sanchez-Salinas A, Gonzalez-Navarro A, Ortiz-Maldonado V, Delgado J, Prosper F, Juan M, Martinez-Lopez J, Moraleda JM, Mateos MV, Urbano-Ispizua A, Paiva B, Pascal M, Fernandez de Larrea C. Biomarkers of efficacy and safety of the academic BCMA-CART ARI0002h for the treatment of refractory multiple myeloma. Clin Cancer Res. 2024 Mar 11. doi: 10.1158/1078-0432.CCR-23-3759. Online ahead of print. PubMed PMID: 38466644.

AÑO: 2024; IF: 11.5

38466644

Oliver-Caldes A, Gonzalez-Calle V, Cabanas V, Espanol-Rego M, Rodriguez-Otero P, Reguera JL, Lopez-Corral L, Martin-Antonio B, Zabaleta A, Inoges S, Varea S, Rosinol L, Lopez-Diaz de Cerio A, Tovar N, Jimenez R, Lopez-Parra M, Rodriguez-Lobato LG, Sanchez-Salinas A, Olesti E, Calvo-Orteu M, Delgado J, Perez-Simon JA, Paiva B, Prosper F, Saez-Penataro J, Juan M, Moraleda JM, Mateos MV, Pascal M, Urbano-Ispizua A, Fernandez de Larrea C. Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study. Lancet Oncol. 2023 Aug;24(8):913-924. doi: 10.1016/S1470-2045(23)00222-X. Epub 2023 Jul 3. PubMed PMID: 37414060.

AÑO: 2023; IF: 51.1

37414060

Puig N, Contreras MT, Agullo C, Martinez-Lopez J, Oriol A, Blanchard MJ, Rios R, Martin J, Inigo MB, Sureda A, Hernandez MT, de la Rubia J, Gonzalez-Calle V, Krsnik I, Cabanas V, Palomera L, Moraleda JM, Bargay J, Cedena MT, Paiva B, Rosinol L, Blade J, San Miguel J, Lahuerta JJ, Mateos MV. Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma. Blood Adv. 2022 Jun 14;6(11):3234-3239. doi: 10.1182/bloodadvances.2021006762. PubMed PMID: 35157768; PubMed Central PMCID: PMC9198943.

AÑO: 2022; IF: 7.5

35157768

Vasco-Mogorrón MA, Campillo JA, Periago A, Cabañas V, Berenguer M, García-Garay MC, Gimeno L, Soto-Ramírez MF, Martínez-Hernández MD, Muro M, Minguela A. Proliferation to Apoptosis Tumor Cell Ratio as a Biomarker to Improve Clinical Management of Pre-Malignant and Symptomatic Plasma Cell Neoplasms. Int J Mol Sci. 2021 Apr 9;22(8). pii: 3895. doi: 10.3390/ijms22083895. PubMed PMID: 33918790; PubMed Central PMCID: PMC8068942.

AÑO: 2021; IF: 6.208

33918790

Vasco-Mogorrón MA, Campillo JA, Periago A, Cabañas V, Berenguer M, García-Garay MC, Gimeno L, Soto-Ramírez MF, Martínez-Hernández MD, Muro M, Minguela A. Blood-based risk stratification for pre-malignant and symptomatic plasma cell neoplasms to improve patient management. Am J Cancer Res. 2021 Jun 15;11(6):2736-2753. eCollection 2021. PubMed PMID: 34249425; PubMed Central PMCID: PMC8263680.

AÑO: 2021; IF: 5.942

34249425